Javascript must be enabled to continue!
Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma
View through CrossRef
AbstractVelpatasvir (VLP) is a new, oral, direct‐acting antiviral with potent inhibitory activity against all hepatitis C virus (HCV) genotypes. A highly sensitive, simple, fast and specific one fluorometric method for determination of VLP in the presence of sofosbuvir was developed and validated. The fluorescence behavior of VLP in different organic solvents was examined and explained. Methanol was concluded to be the best sensitizing reagent. The native fluorescence intensity of VLP was accomplished at 383 nm with 339 nm for excitation wavelength. The impacts of experimental variables included pH, various organized media, and time of stability were examined and optimized. A linear relationship was achieved between the VLP concentration and the fluorescence intensity in a range of 5 to 5 × 103 ng mL−1 with 0.70 and 0.23 ng mL−1, for quantitation and detection limits respectively. The proposed method was utilized for analyzing of VLP in human plasma and additionally expanded to examine the stability of VLP after its exposure to various stress conditions, like oxidative, alkaline, acidic, UV, daylight and sunlight conditions, according to ICH guidelines. Furthermore, the kinetics of acidic and oxidative degradations of VLP was examined. Moreover, the half‐life times of the reaction (t1/2) and the first‐order reaction rate constants were estimated. Finally, a suggestion for the degradation pathway was presented.
Title: Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma
Description:
AbstractVelpatasvir (VLP) is a new, oral, direct‐acting antiviral with potent inhibitory activity against all hepatitis C virus (HCV) genotypes.
A highly sensitive, simple, fast and specific one fluorometric method for determination of VLP in the presence of sofosbuvir was developed and validated.
The fluorescence behavior of VLP in different organic solvents was examined and explained.
Methanol was concluded to be the best sensitizing reagent.
The native fluorescence intensity of VLP was accomplished at 383 nm with 339 nm for excitation wavelength.
The impacts of experimental variables included pH, various organized media, and time of stability were examined and optimized.
A linear relationship was achieved between the VLP concentration and the fluorescence intensity in a range of 5 to 5 × 103 ng mL−1 with 0.
70 and 0.
23 ng mL−1, for quantitation and detection limits respectively.
The proposed method was utilized for analyzing of VLP in human plasma and additionally expanded to examine the stability of VLP after its exposure to various stress conditions, like oxidative, alkaline, acidic, UV, daylight and sunlight conditions, according to ICH guidelines.
Furthermore, the kinetics of acidic and oxidative degradations of VLP was examined.
Moreover, the half‐life times of the reaction (t1/2) and the first‐order reaction rate constants were estimated.
Finally, a suggestion for the degradation pathway was presented.
Related Results
To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients
To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients
Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis viruses are the most comm...
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
Hepatitis C virus (HCV) infection, which can cause chronic liver diseases, cirrhosis and hepatocellular carcinoma, is still a major public health problem worldwide. Upon comparing ...
Thin‐layer chromatography/fluorescence detection approach for sensitive and selective determination of hepatitis C virus antiviral (velpatasvir): application to human plasma
Thin‐layer chromatography/fluorescence detection approach for sensitive and selective determination of hepatitis C virus antiviral (velpatasvir): application to human plasma
AbstractA validated thin‐layer chromatography (TLC) method combined with fluorescence detection mode was developed for the selective determination of a recently approved anti‐hepat...
INFLUENCE OF HOST AND VIRAL FACTORS IN HEPATITIS C VIRUS INFECTION: ROLE OF TA REPEAT, IFNL3 AND IFNL4 POLYMORPHISMS IN HCV INFECTION AND OUTCOME OF TREATMENT
INFLUENCE OF HOST AND VIRAL FACTORS IN HEPATITIS C VIRUS INFECTION: ROLE OF TA REPEAT, IFNL3 AND IFNL4 POLYMORPHISMS IN HCV INFECTION AND OUTCOME OF TREATMENT
Hepatitis C virus (HCV) is a serious public health problem affecting 170 million carriers worldwide. It is a leading cause of chronic hepatitis, cirrhosis, and liver cancer and is ...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
This case report describes of a pharmacokinetic drug–drug interaction
between crizotinib, a tyrosine kinase inhibitor, and
sofosbuvir/velpatasvir, a direct-acting antiviral drug, l...
Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
Medicaid prior authorization (PA) policies for treatment of hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapy are changing. We aimed to evaluate effects of changes...
Efficacy of Sofosbuvir plus Ribavirin in treatment of cirrhotic patients with HCV genotype 2 and 3 infections in Pakistan
Efficacy of Sofosbuvir plus Ribavirin in treatment of cirrhotic patients with HCV genotype 2 and 3 infections in Pakistan
Hepatitis C virus (HCV) is one of the leading causes of liver cirrhosis. Adjunctive therapy of ribavirin and interferon is commonly used against HCV infection, but it has wide dive...

